Literature DB >> 28787403

Loxo TRK inhibitor data wows oncologists.

Elie Dolgin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28787403     DOI： 10.1038/nbt0817-694

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  7 in total

1.  NCI-MATCH pairs tumor mutations with matching drugs.

Authors:  Vicki Brower
Journal:  Nat Biotechnol       Date:  2015-08       Impact factor: 54.908

2.  Oncologists await historic first: a pan-tumor predictive marker, for immunotherapy.

Authors:  Ken Garber
Journal:  Nat Biotechnol       Date:  2017-04-11       Impact factor: 54.908

3.  Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).

Authors:  Alexander Drilon; Salvatore Siena; Sai-Hong Ignatius Ou; Manish Patel; Myung Ju Ahn; Jeeyun Lee; Todd M Bauer; Anna F Farago; Jennifer J Wheler; Stephen V Liu; Robert Doebele; Laura Giannetta; Giulio Cerea; Giovanna Marrapese; Michele Schirru; Alessio Amatu; Katia Bencardino; Laura Palmeri; Andrea Sartore-Bianchi; Angelo Vanzulli; Sara Cresta; Silvia Damian; Matteo Duca; Elena Ardini; Gang Li; Jason Christiansen; Karey Kowalski; Ann D Johnson; Rupal Patel; David Luo; Edna Chow-Maneval; Zachary Hornby; Pratik S Multani; Alice T Shaw; Filippo G De Braud
Journal:  Cancer Discov       Date:  2017-02-09       Impact factor: 39.397

4.  Outlook for NGF inhibitor painkiller class brightens.

Authors:  Kelly Rae Chi
Journal:  Nat Biotechnol       Date:  2016-07-12       Impact factor: 54.908

5.  Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.

Authors:  Mariangela Russo; Sandra Misale; Ge Wei; Giulia Siravegna; Giovanni Crisafulli; Luca Lazzari; Giorgio Corti; Giuseppe Rospo; Luca Novara; Benedetta Mussolin; Alice Bartolini; Nicholas Cam; Roopal Patel; Shunqi Yan; Robert Shoemaker; Robert Wild; Federica Di Nicolantonio; Andrea Sartore Bianchi; Gang Li; Salvatore Siena; Alberto Bardelli
Journal:  Cancer Discov       Date:  2015-11-06       Impact factor: 39.397

6.  What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).

Authors:  A Drilon; G Li; S Dogan; M Gounder; R Shen; M Arcila; L Wang; D M Hyman; J Hechtman; G Wei; N R Cam; J Christiansen; D Luo; E C Maneval; T Bauer; M Patel; S V Liu; S H I Ou; A Farago; A Shaw; R F Shoemaker; J Lim; Z Hornby; P Multani; M Ladanyi; M Berger; N Katabi; R Ghossein; A L Ho
Journal:  Ann Oncol       Date:  2016-02-15       Impact factor: 32.976

7.  Infantile Fibrosarcoma With NTRK3-ETV6 Fusion Successfully Treated With the Tropomyosin-Related Kinase Inhibitor LOXO-101.

Authors:  Ramamoorthy Nagasubramanian; Julie Wei; Paul Gordon; Jeff C Rastatter; Michael C Cox; Alberto Pappo
Journal:  Pediatr Blood Cancer       Date:  2016-04-19       Impact factor: 3.167
  7 in total
  1 in total

1.  Roche pays $1.7 billion to target tumors' genetic signatures.

Authors: 
Journal:  Nat Biotechnol       Date:  2018-02-06       Impact factor: 54.908
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.